

9-16 and Tables IX- XII (see page 57 through page 64). Additional support may be found for example in the title, summary of the invention (see page 4, line 27), detailed and description of the invention (see page 10, line 17), which refer to the compounds of the present invention as 4-pyrimidineamine derivatives. Applicants further submit that in reading the specification, one skilled in the art would readily recognize the typographical error in the structure of the compounds of formula (I) and further that one skilled in the art would readily recognize the required correction.


Applicants maintain that the amendments are fully supported by the specification and that no new matter is being added.

After entry of the amendments, Claims 1-66 will remain pending and under consideration. Favorable consideration of this application is respectfully requested..

Attached hereto is a marked up version of the changes made to the specification and claims by the current amendment. The attached pages are captioned **"Version with Markings to Show Changes Made"**.

Should the Examiner have any questions he or she is invited to contact the undersigned at the telephone number provided below.

Respectfully submitted,

  
Myra McCormack  
Attorney for Applicants  
Reg. No. 36,602


Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-6932  
Dated: February 11, 2002

Attachments

**Version with Markings to Show Changes Made**

**In the Specification:**


**Page 4, the first paragraph of the Summary of the Invention has been amended to read:**




wherein

**At Page 10, the first paragraph of the Detailed Description of the Invention has been amended to read:**

The present invention provides novel neuroprotective 4-pyrimidineamine derivatives of the general formula (I)







or a pharmaceutically acceptable salt thereof, wherein  $R^{20}$ ,  $R^{21}$ ,  $p$ ,  $q$ ,  $R^{22}$  and  $R^{23}$  are as previously defined, useful in reducing ischemic death in a cell population.


**In the Claims**

**Claim 40 has been amended to read:**

40. (Amended Once) A compound of the formula



wherein



wherein  $R^A$  and  $R^B$  are independently selected from hydrogen, alkyl, halogenated alkyl, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aryl, aralkyl, cycloalkyl, cycloalkyl-alkyl, heteroaryl, heteroaryl-alkyl, alkoxyalkyl, aryloxy, aryloxyalkyl, alkoxycarbonylalkyl and dehydroabietyl; wherein the aryl cycloalkyl, heteroaryl or heterocycloalkyl portion of any of the groups is optionally substituted with one or more substituents independently selected from halogen, alkyl, alkoxy, halogenated alkyl, amino, alkylamino, dialkylamino, arylamino, aralkylamino, amido, alkylamido, dialkylamido, arylamido, aralkylamido, azo, nitro, cyano, aryl, aralkyl, aryloxy, carboxy, alkoxycarbonyl, aryloxy carbonyl, alkylthio, arylthio, alkylsulfonylN(H), or alkylsulfonylN(alkyl);

alternatively  $R^A$  and  $R^B$  are taken together with the nitrogen atom to which they are bound to form a compound selected from the group heteroaryl and heterocycloalkyl; wherein the heteroaryl or heterocycloalkyl is optionally substituted with one or more substituents independently selected from halogen, alkyl, alkoxy, alkoxycarbonyl, halogenated alkyl, alkylcarbonyl, amino, alkylamino, dialkylamino, arylamino, azo, nitro or cyano;

$R^C$  is selected from the group consisting of alkyl, aralkyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, ( $\pm$ )-N-benzoyl-aminoalkylcarbonyl or [3aS-(3 $\alpha$ ,4 $\beta$ ,6 $\alpha$ )]-hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-alkylcarbonyl;

$R^D$  is selected from alkyl, aryl, aralkyl, ( $\pm$ )-N-benzoyl-aminoalkyl, [3aS-(3 $\alpha$ ,4 $\beta$ ,6 $\alpha$ )]-hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-alkyl or biphenyl; wherein the alkyl or aryl portion of the alkyl, aryl or aralkyl group is optionally substituted with one or more substituents

independently selected from halogen, alkyl, alkoxy, amino, alkylamino, dialkylamino, azo, nitro, cyano, or trifluoromethyl);

$R^{21}$  is selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl and aralkylcarbonyl; wherein the aryl portion is optionally substituted with one or more substituents independently selected from halogen, alkyl, alkoxy, halogenated alkyl or nitro;

p is an integer selected from 0 to 3;

q is an integer selected from 0 to 3;

$R^{22}$  and  $R^{23}$  are each independently selected from the group consisting of halogen, alkyl, alkoxy, amino, alkylamino, dialkylamino, nitro, cyano, carboxy, alkoxycarbonyl, aryloxy, aminocarbonyl, alkylaminocarbonyl and dialkylaminocarbonyl;

or a pharmaceutically acceptable salt thereof.